408 related articles for article (PubMed ID: 34384473)
21. Current and Future Biomarkers in the Management of Renal Cell Carcinoma.
Reese S; Calderon L; Khaleel S; Hakimi AA
Urol Clin North Am; 2023 Feb; 50(1):151-159. PubMed ID: 36424079
[TBL] [Abstract][Full Text] [Related]
22. Pathobiology, prognosis, and targeted therapy for renal cell carcinoma: exploiting the hypoxia-induced pathway.
Pantuck AJ; Zeng G; Belldegrun AS; Figlin RA
Clin Cancer Res; 2003 Oct; 9(13):4641-52. PubMed ID: 14581333
[TBL] [Abstract][Full Text] [Related]
23. Action of YM155 on clear cell renal cell carcinoma does not depend on survivin expression levels.
Sim MY; Huynh H; Go ML; Yuen JSP
PLoS One; 2017; 12(6):e0178168. PubMed ID: 28582447
[TBL] [Abstract][Full Text] [Related]
24. Up-regulation of hypoxia-inducible factor 2alpha in renal cell carcinoma associated with loss of Tsc-2 tumor suppressor gene.
Liu MY; Poellinger L; Walker CL
Cancer Res; 2003 May; 63(10):2675-80. PubMed ID: 12750296
[TBL] [Abstract][Full Text] [Related]
25. Significance of PI3K signalling pathway in clear cell renal cell carcinoma in relation to VHL and HIF status.
Tumkur Sitaram R; Landström M; Roos G; Ljungberg B
J Clin Pathol; 2021 Apr; 74(4):216-222. PubMed ID: 32467322
[TBL] [Abstract][Full Text] [Related]
26. P53 and MDM2 Over-expression and Five-year Survival of Kidney Cancer Patients Undergoing Radical Nephrectomy--Iranian Experience.
Abolhasani M; Salarinejad S; Asgari M
Asian Pac J Cancer Prev; 2015; 16(12):5043-7. PubMed ID: 26163638
[TBL] [Abstract][Full Text] [Related]
27. Influence of survivin (BIRC5) and caspase-9 (CASP9) functional polymorphisms in renal cell carcinoma development: a study in a southern European population.
Marques I; Teixeira AL; Ferreira M; Assis J; Lobo F; Maurício J; Medeiros R
Mol Biol Rep; 2013 Aug; 40(8):4819-26. PubMed ID: 23645041
[TBL] [Abstract][Full Text] [Related]
28. Carbonic anhydrase IX in renal cell carcinoma: implications for prognosis, diagnosis, and therapy.
Stillebroer AB; Mulders PF; Boerman OC; Oyen WJ; Oosterwijk E
Eur Urol; 2010 Jul; 58(1):75-83. PubMed ID: 20359812
[TBL] [Abstract][Full Text] [Related]
29. MALAT1 accelerates the development and progression of renal cell carcinoma by decreasing the expression of miR-203 and promoting the expression of BIRC5.
Zhang H; Li W; Gu W; Yan Y; Yao X; Zheng J
Cell Prolif; 2019 Sep; 52(5):e12640. PubMed ID: 31250518
[TBL] [Abstract][Full Text] [Related]
30. Value of p53 as a prognostic marker in histologic subtypes of renal cell carcinoma: a systematic analysis of primary and metastatic tumor tissue.
Zigeuner R; Ratschek M; Rehak P; Schips L; Langner C
Urology; 2004 Apr; 63(4):651-5. PubMed ID: 15072872
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of Transglutaminase 2 but Not of MDM2 Has a Significant Therapeutic Effect on Renal Cell Carcinoma.
Kang JH; Lee SH; Lee JS; Oh SJ; Ha JS; Choi HJ; Kim SY
Cells; 2020 Jun; 9(6):. PubMed ID: 32560270
[TBL] [Abstract][Full Text] [Related]
32. Current updates and future perspectives on the management of renal cell carcinoma.
Singh D
Life Sci; 2021 Jan; 264():118632. PubMed ID: 33115605
[TBL] [Abstract][Full Text] [Related]
33. Inhibitor of growth 4 inhibits cell proliferation, migration, and induces apoptosis of renal cell carcinoma cells.
Sun J; Xie L; Lv J; Zhang W; Lv J; Liang Y; Geng Y; Li X
J Cell Biochem; 2019 Apr; 120(4):6709-6717. PubMed ID: 30390334
[TBL] [Abstract][Full Text] [Related]
34. Expanding the morphologic spectrum of chromophobe renal cell carcinoma: A study of 8 cases with papillary architecture.
Michalova K; Tretiakova M; Pivovarcikova K; Alaghehbandan R; Perez Montiel D; Ulamec M; Osunkoya A; Trpkov K; Yuan G; Grossmann P; Sperga M; Ferak I; Rogala J; Mareckova J; Pitra T; Kolar J; Michal M; Hes O
Ann Diagn Pathol; 2020 Feb; 44():151448. PubMed ID: 31918172
[TBL] [Abstract][Full Text] [Related]
35. MDM2 SNP309 polymorphism as risk factor for susceptibility and poor prognosis in renal cell carcinoma.
Hirata H; Hinoda Y; Kikuno N; Kawamoto K; Suehiro Y; Tanaka Y; Dahiya R
Clin Cancer Res; 2007 Jul; 13(14):4123-9. PubMed ID: 17634539
[TBL] [Abstract][Full Text] [Related]
36. Gene expression analysis of renal carcinoma: adipose differentiation-related protein as a potential diagnostic and prognostic biomarker for clear-cell renal carcinoma.
Yao M; Tabuchi H; Nagashima Y; Baba M; Nakaigawa N; Ishiguro H; Hamada K; Inayama Y; Kishida T; Hattori K; Yamada-Okabe H; Kubota Y
J Pathol; 2005 Feb; 205(3):377-87. PubMed ID: 15682440
[TBL] [Abstract][Full Text] [Related]
37. Hereditary renal cell carcinoma syndromes: diagnosis, surveillance and management.
Maher ER
World J Urol; 2018 Dec; 36(12):1891-1898. PubMed ID: 29680948
[TBL] [Abstract][Full Text] [Related]
38. [Renal cell carcinoma].
Fornara P; Hoda MR
Urologe A; 2011 Sep; 50 Suppl 1():219-22. PubMed ID: 21837488
[TBL] [Abstract][Full Text] [Related]
39. Hypoxia-inducing factor (HIF)-1α-derived peptide capable of inducing cancer-reactive cytotoxic T lymphocytes from HLA-A24
Minami T; Matsumura N; Sugimoto K; Shimizu N; De Velasco M; Nozawa M; Yoshimura K; Harashima N; Harada M; Uemura H
Int Immunopharmacol; 2017 Mar; 44():197-202. PubMed ID: 28110220
[TBL] [Abstract][Full Text] [Related]
40. miR-33a inhibits cell growth in renal cancer by downregulation of MDM4 expression.
Jiang K; Sun F; Zhu J; Luo G; Ban Y; Zhang P
Mol Genet Genomic Med; 2019 Aug; 7(8):e833. PubMed ID: 31250570
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
